Teva gets CRL for Huntington's candidate

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) received an FDA complete response letter for SD-809 deutetrabenazine to treat chorea associated with Huntington's disease (HD). The company plans to submit its response to FDA next quarter.

Teva gained the candidate in May 2015 through its $3.5 billion acquisition of Auspex Pharmaceuticals Inc., which had developed SD-809 as Austedo (see BioCentury, April 6, 2015). ...